98%
921
2 minutes
20
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s00431-022-04762-8 | DOI Listing |
Am J Health Syst Pharm
August 2025
Department of Pharmacy, Mayo Clinic, Rochester, MN, USA.
Purpose: No consistent recommendations exist on how best to educate pharmacists to facilitate implementation of new evidence-based practices. This study aimed to determine whether spaced learning was more effective than traditional education when learning a new evidence-based practice (β-lactam therapeutic drug monitoring, or TDM).
Summary: β-lactam TDM was implemented in a phased fashion at Mayo Clinic in Rochester.
J Clin Pharmacol
August 2025
Division of Translational and Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
We previously developed a population pharmacokinetic (PopPK) model for meropenem in pediatric intensive care unit patients accounting for effect of body size, maturation, and kidney function on clearance. This study aimed to extrapolate meropenem exposure to neonates and young infants using the pediatric PopPK model and to validate the predictions using external data. An independent dataset was obtained from the regulations.
View Article and Find Full Text PDFEur J Drug Metab Pharmacokinet
September 2025
Faculté de pharmacie, Université de Montréal, 2940 chemin de Polytechnique, Montréal, QC, H3T 1J4, Canada.
Background And Objective: In a recent simulation-based study, we found that sample size had minimal influence on the external evaluation of population pharmacokinetic (PK) models. However, the applicability of these findings to clinical data remains unexplored. This study aims to validate our previous simulation-based results using real-world clinical data.
View Article and Find Full Text PDFMedicina (Kaunas)
June 2025
Orthopaedic Unit, Department of Surgery, Bambino Gesù Children's Hospital, 00165 Rome, Italy.
Surgical site infections (SSIs) significantly impact pediatric spinal deformity surgery. Considering the increased risk of Gram-negative infections in neuromuscular scoliosis (NMS), broader antibiotic coverage could be advantageous. Some studies suggest extending this approach to all scoliosis etiologies to reduce SSI rates.
View Article and Find Full Text PDF